|
|
Article: NewCo News With Funding in Hand, Aragon on a Seek and Destroy Mission.
- Article from:
- BIOWORLD Today
- Article date:
- August 27, 2009
- Author:
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Byline: Trista Morrison, Staff Writer
Aragon Pharmaceuticals Inc.'s name says it all: The company is targeting the androgen receptor -- abbreviated in scientific circles as "AR" -- and wants it gone.
The technology behind Aragon came from Charles Sawyers, chairman of human oncology at Memorial Sloan-Kettering Cancer Center, and Michael Jung, chemistry professor at the University of California, Los Angeles.
Sawyers wanted to understand why men with prostate cancer eventually become resistant to hormone therapy. He traced the problem to an elevated level of androgen receptors and developed animal models to prove his theory.
In 2008, his ...